Effects of the COVID-19 Pandemic on Caregivers of Young Children with Sickle Cell Disease Enrolled in the Engage-HU Trial
Background: Hydroxyurea (HU) is the primary medication used to prevent the significant medical and neurologic morbidities of pediatric sickle cell disease (SCD; HbSS or HbSB0 thalassemia). Despite the benefits of HU, it remains under‐utilized likely due to lack of clinician knowledge/training and ne...
Saved in:
Published in | Blood Vol. 138; no. Supplement 1; p. 1891 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Elsevier Inc
23.11.2021
American Society of Hematology. Published by Elsevier Inc |
Online Access | Get full text |
Cover
Loading…
Be the first to leave a comment!